The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial (NCT06871111)
🩺 Plain-English Summary (8th-Grade Level)
The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) trial is a single center prospective adaptive phase 1b clinical trial in patients who are hospitalized with complications of liver disease and have low fecal metabolite levels (butyrate and deoxycholic acid). The study intervention is 1 of 9 novel live Commensal Consortia each containing eight commensal bacterial strains derived from healthy donors. The primary objective of the study is to determine safety and tolerability of Commensal Consortia administration.
Who can join: Review the eligibility criteria below.
Location: The University of Chicago Medical Center — Chicago, Illinois
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- The University of Chicago Medical Center — Chicago, Illinois
📞 Contact the Study Coordinator
Phone: (773) 702-6331
Email: matthew.odenwald@uchicagomedicine.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Liver Diseases
- Coronavirus Disease 2019 (Covid-19) Impact on Alcohol-related Liver Disease Patient Outcomes, Care and Alcohol Use — San Francisco, California
- Liver Cancer Prevention Randomized Control Trial — Houston, Texas
- RESTORE Declined Livers Study — St Louis, Missouri
- Liver Micro Flow - MRI — Madison, Wisconsin
- MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease — Chicago, Illinois
Explore by condition: All Liver Diseases clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.